| Year |
Citation |
Score |
| 2022 |
Kiss B, Krámos B, Laszlovszky I. Potential Mechanisms for Why Not All Antipsychotics Are Able to Occupy Dopamine D Receptors in the Brain . Frontiers in Psychiatry. 13: 785592. PMID 35401257 DOI: 10.3389/fpsyt.2022.785592 |
0.312 |
|
| 2021 |
Laszlovszky I, Barabássy Á, Németh G. Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety. Advances in Therapy. PMID 34091867 DOI: 10.1007/s12325-021-01797-5 |
0.364 |
|
| 2021 |
Barabássy Á, Sebe B, Acsai K, Laszlovszky I, Szatmári B, Earley WR, Németh G. Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies. Neuropsychiatric Disease and Treatment. 17: 957-970. PMID 33854317 DOI: 10.2147/NDT.S301225 |
0.347 |
|
| 2019 |
Laszlovszky I, Kiss B, Barabassy A, Kapas M, Nemeth G. [Cariprazine, a new type - dopamine D₃ receptor preferring - partial agonist atypical antipsychotic for the treatment of schizophrenia and the primary negative symptoms]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet Lapja = Official Journal of the Hungarian Association of Psychopharmacology. 21: 103-118. PMID 31537751 |
0.339 |
|
| 2019 |
Fleischhacker W, Galderisi S, Laszlovszky I, Szatmári B, Barabássy Á, Acsai K, Szalai E, Harsányi J, Earley W, Patel M, Németh G. The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors. European Psychiatry : the Journal of the Association of European Psychiatrists. 58: 1-9. PMID 30738380 DOI: 10.1016/j.eurpsy.2019.01.015 |
0.341 |
|
| 2019 |
Laszlovszky I, Barabassy A, Kiss B, Szatmári B, Adham N, Earley W, Németh G. Cariprazine, a selective dopamine D3 receptor partial agonist with unique features to treat schizophrenia negative and cognitive symptoms European Neuropsychopharmacology. 29: S398-S399. DOI: 10.1016/j.euroneuro.2018.11.604 |
0.307 |
|
| 2018 |
Marder S, Fleischhacker WW, Earley W, Lu K, Zhong Y, Németh G, Laszlovszky I, Szalai E, Durgam S. Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 30470662 DOI: 10.1016/j.euroneuro.2018.10.008 |
0.35 |
|
| 2017 |
Durgam S, Earley W, Lu K, Németh G, Laszlovszky I, Volk S, Litman RE. Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis. International Journal of Clinical Practice. PMID 29119668 DOI: 10.1111/ijcp.13037 |
0.328 |
|
| 2017 |
Nasrallah HA, Earley W, Cutler AJ, Wang Y, Lu K, Laszlovszky I, Németh G, Durgam S. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis. Bmc Psychiatry. 17: 305. PMID 28836957 DOI: 10.1186/s12888-017-1459-z |
0.348 |
|
| 2017 |
Earley W, Durgam S, Lu K, Laszlovszky I, Debelle M, Kane JM. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies. International Clinical Psychopharmacology. PMID 28692485 DOI: 10.1097/YIC.0000000000000187 |
0.325 |
|
| 2017 |
Cutler AJ, Durgam S, Wang Y, Migliore R, Lu K, Laszlovszky I, Németh G. Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study. Cns Spectrums. 1-12. PMID 28478771 DOI: 10.1017/S1092852917000220 |
0.362 |
|
| 2016 |
Durgam S, Greenberg WM, Li D, Lu K, Laszlovszky I, Nemeth G, Migliore R, Volk S. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study. Psychopharmacology. PMID 27807604 DOI: 10.1007/s00213-016-4450-3 |
0.346 |
|
| 2016 |
Girgis RR, Slifstein M, D'Souza D, Lee Y, Periclou A, Ghahramani P, Laszlovszky I, Durgam S, Adham N, Nabulsi N, Huang Y, Carson RE, Kiss B, Kapás M, Abi-Dargham A, et al. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO. Psychopharmacology. PMID 27525990 DOI: 10.1007/S00213-016-4382-Y |
0.343 |
|
| 2016 |
Durgam S, Earley W, Li R, Li D, Lu K, Laszlovszky I, Fleischhacker WW, Nasrallah HA. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. Schizophrenia Research. PMID 27427558 DOI: 10.1016/j.schres.2016.06.030 |
0.34 |
|
| 2016 |
Citrome L, Durgam S, Lu K, Ferguson P, Laszlovszky I. The effect of cariprazine on hostility associated with schizophrenia: post hoc analyses from 3 randomized controlled trials. The Journal of Clinical Psychiatry. 77: 109-15. PMID 26845266 DOI: 10.4088/JCP.15m10192 |
0.36 |
|
| 2016 |
Németh G, Debelle M, Laszlovszky I, Szalai E, Szatmári B, Harsányi J, Barabássy Á, Durgam S, Bitter I, Galderisi S. Monotherapy treatment with cariprazine for the treatment of predominant negative symptoms of patients with schizophrenia: A double-blind, active comparator-controlled trial European Psychiatry. 33: s256-s257. DOI: 10.1016/J.Eurpsy.2016.01.652 |
0.346 |
|
| 2015 |
Kane JM, Zukin S, Wang Y, Lu K, Ruth A, Nagy K, Laszlovszky I, Durgam S. Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results From an International, Phase III Clinical Trial. Journal of Clinical Psychopharmacology. 35: 367-73. PMID 26075487 DOI: 10.1097/JCP.0000000000000346 |
0.316 |
|
| 2015 |
Durgam S, Starace A, Li D, Migliore R, Ruth A, Németh G, Laszlovszky I. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disorders. 17: 63-75. PMID 25056368 DOI: 10.1111/bdi.12238 |
0.324 |
|
| 2015 |
Debelle M, Németh G, Szalai E, Szatmári B, Harsányi J, Barabassy A, Laszlovszky I. P.3.d.053 Cariprazine as monotherapy for the treatment of schizophrenia patients with predominant negative symptoms: a double-blind, active controlled trial European Neuropsychopharmacology. 25: S510. DOI: 10.1016/S0924-977X(15)30701-X |
0.335 |
|
| 2014 |
Durgam S, Starace A, Li D, Migliore R, Ruth A, Németh G, Laszlovszky I. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophrenia Research. 152: 450-7. PMID 24412468 DOI: 10.1016/j.schres.2013.11.041 |
0.353 |
|
| Show low-probability matches. |